Kaimi Biology completed nearly 170 million yuan in Pre-A round financing.

36Kr learned from Kemi Biotech that recently, "Kemi Biotech", a company focused on the development of innovative therapeutic vaccines, announced the official completion of its Pre-A round of financing. This round of financing was oversubscribed, with a total scale of nearly 170 million yuan. This financing was led by SDIC Venture Capital, followed by Zhongke Chuangxing, Guosheng Innovation, and existing shareholder Longpan Investment. The funds raised will be used to accelerate the global early-stage clinical development of the core products SN3001 (a therapeutic vaccine for prostate cancer) and SN2001 (an immunotherapeutic vaccine for chronic hepatitis B), upgrade the R & D center, and continue to plan for subsequent oncology therapeutic vaccine products.